Bone-pathobolism treating agent

Details Bone-pathobolism treating agent Bone-pathobolism treating agent

2005-07-19

2005-07-19

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S002600, C424S009100, C530S350000, C536S023100, C435S069100

Reexamination Certificate

active

06919312

ABSTRACT:
A novel bone-pathobolism treating agent is provided. A bone-pathobolism treating agent comprising at least one substance selected from the group consisting of osteoclastogenesis inhibitory factor (OCIF), its homologs, and its variants, and a polysaccharide or its derivatives. As the polysaccharide or its derivatives, heparin, dextran sulfate and the like can be used. A bone-pathobolism treating agent is provided which has excellent therapeutic effect on bone-pathobolism such as osteoporosis, hypercalcemia, or chronic articular rheumatism and persistance of the activity. The agent is useful as a medicine.

REFERENCES:
patent: 5545722 (1996-08-01), Naka
patent: 5736506 (1998-04-01), Naka
patent: 6015938 (2000-01-01), Boyle et al.
patent: 6214838 (2001-04-01), Sohda et al.
patent: 6284485 (2001-09-01), Boyle et al.
patent: 6284728 (2001-09-01), Boyle et al.
patent: 6284740 (2001-09-01), Boyle et al.
patent: 6288032 (2001-09-01), Boyle et al.
patent: 6369027 (2002-04-01), Boyle et al.
patent: 6613544 (2003-09-01), Boyle et al.
patent: 6693175 (2004-02-01), Yano et al.
patent: 2002/0004207 (2002-01-01), Yano et al.
patent: 2002/0051969 (2002-05-01), Goto et al.
patent: 2003/0045456 (2003-03-01), Yamamoto et al.
patent: 2003/0139325 (2003-07-01), Yamamoto et al.
patent: 2003/0153048 (2003-08-01), Goto et al.
patent: 2003/0181418 (2003-09-01), Kumakura et al.
patent: 2003/0207827 (2003-11-01), Boyle et al.
patent: 2003/0216297 (2003-11-01), Kumakura et al.
patent: 0 784 093 (1997-07-01), None
patent: 0 816 380 (1998-07-01), None
patent: 0 874 045 (1998-10-01), None
patent: 0 911 342 (1999-04-01), None
patent: 0 974 671 (2000-01-01), None
patent: 1 127 578 (2001-08-01), None
patent: 1 270 015 (2003-01-01), None
patent: 1 270 015 (2004-02-01), None
patent: 96/26217 (1996-08-01), None
patent: 97/23614 (1997-07-01), None
patent: WO 98/46211 (1998-10-01), None
patent: 99/15691 (1999-04-01), None
patent: WO 01/03719 (2001-01-01), None
patent: WO 01/03719 (2001-01-01), None
patent: WO 01/17543 (2001-03-01), None
patent: WO 01/17543 (2001-03-01), None
patent: WO 01/44472 (2001-06-01), None
patent: 03/074084 (2003-09-01), None
Supplementary Partial European Search Report, European Application No. EP 99 95 2793 (European Published Application No. EP 1 127 578 A1) (Oct. 27, 2004).
J. Body, “Current and Future Directions in Medical Therapy:Hypercalcemia”, CANCER Supplement,88 (12):3054-3058 (2000).
E. Romas et al., “Involvement of Receptor Activator of NFκB Ligand and Tumor Necrosis Factor-α in Bone Destruction in Rheumatoid Arthritis”,Bone,30(2):340-346 (2002).
B. Fautrel et al., “Cost of Illness Studies in Rheumatic Diseases”,Current Opinion in Rheumatology,14:121-126 (2002).
M. Iqbal et al., “Osteoporosis: A Review”,Missouri Medicine,99(1):19-24 (2002).
J. White et al., “Postmenopausal Hormone Replacement: Historical Perspectives and Current Concerns”,Clinical Excellence for Nurse Practitioners,4(5):277-285 (2000).
J. Green et al., “Renal Tolerability Profile of Novel, Potent Bisphosphonates in Two Short-Term Rat Models”,Pharmacology and Toxicology,80:225-230 (1997).
S. Porcel et al., “Anaphylaxis to calcitonin”,Allergologia et Immunopathologia,28(4), 243-245 (2000).
W. S. Simonet et al., “Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density”Cell,89:309-319 (1997).
Tomoyasu, et al., Characterization of Monomeric and Homodimeric Forms of Osteoclastogenesis Inhibitory Factor, Biochemical and Biophysical Research Communications 23, 382-387 (1998).
Yamamoto, et al., Hypocalcemic Effect of Osteoclastogenesis Inhibitory Factor/Osteoprotegerin in the Thyroparathyroidectomized Rat, Endocrinology vol. 139, No. 9 (1998), p. 4012-4015.
Chowdhury, et al., Effects of Heparin on Osteoclast Activity, Journal of Bone and Mineral Research, vol. 7, No. 7, (1992), pp 771-777.
Cochran and Abernathy, Modulation of Bone Resorption by Glycosaminoglycans: Effects of Parathyroid Hormone and Interleukin-1, Bone, 9, 331-335 (1988).
Nobuyuki, et al., Remedy for Osteopathy, Publication No. 62-201825 (1987). abstract only.
Chemical Abstracts vol. 123, p. 662, (1995).

Affiliated with

Also associated with

Rating

Bone-pathobolism treating agent does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bone-pathobolism treating agent, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bone-pathobolism treating agent will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3393774